Literature DB >> 3068292

Clinical applications of GnRH analogs.

G Forti1.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3068292     DOI： 10.1007/bf03350939

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  61 in total

Review 1.  Binding and activation of gonadotropin-releasing hormone receptors in pituitary and gonadal cells.

Authors:  Z Naor; G V Childs
Journal:  Int Rev Cytol       Date:  1986

2.  Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.

Authors:  M R Henzl; S L Corson; K Moghissi; V C Buttram; C Berqvist; J Jacobson
Journal:  N Engl J Med       Date:  1988-02-25       Impact factor: 91.245

3.  Treatment of breast cancer with gonadotropin-releasing hormone.

Authors:  A Manni; R Santen; H Harvey; A Lipton; D Max
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

4.  Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression.

Authors:  R Fleming; J R Coutts
Journal:  Fertil Steril       Date:  1986-02       Impact factor: 7.329

5.  Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments.

Authors:  J G Klijn
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

6.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

Review 7.  Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.

Authors:  P A Boepple; M J Mansfield; M E Wierman; C R Rudlin; H H Bode; J F Crigler; J D Crawford; W F Crowley
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

8.  Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.

Authors:  A Lemay; N Faure; F Labrie; A T Fazekas
Journal:  Fertil Steril       Date:  1985-06       Impact factor: 7.329

9.  Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.

Authors:  C P West; M A Lumsden; S Lawson; J Williamson; D T Baird
Journal:  Fertil Steril       Date:  1987-07       Impact factor: 7.329

10.  Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.

Authors:  M Filicori; E Campaniello; L Michelacci; A Pareschi; P Ferrari; G Bolelli; C Flamigni
Journal:  J Clin Endocrinol Metab       Date:  1988-02       Impact factor: 5.958
View more
  1 in total

1.  Stability of gonadorelin and triptorelin in aqueous solution.

Authors:  V J Helm; B W Müller
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.